The Diabetes–Viral Respiratory Syndemic: Pathophysiological Insights and Precision Management: A Scoping Review
Open Access
Abstract
Background/Objectives: Viral respiratory tract infections (VRTIs) in patients with diabetes mellitus (DM) are characterized by a severity gap rather than an infection gap. This review synthesizes evidence from the 2023–2026 respiratory seasons to provide a post-pandemic framework for managing the synergistic metabolic and viral threats in this population. Materials and Methods: A scoping review of literature from PubMed, Scopus, and Embase (2023–2026) was conducted, focusing on clinical outcomes and mechanistic interactions between DM and emerging respiratory pathogens. Results: Recent data identify human Metapneumovirus (hMPV) and adenovirus as significant threats to diabetic hosts, with mortality risks equivalent to seasonal influenza (HR 1.00 for hMPV vs. influenza). The two-hit model combines a baseline of innate immune paralysis, characterized by impaired neutrophil chemo-taxis and mechanical SP-D dysfunction, with a cellular signaling environment primed for cytokine overreaction by epigenetic metabolic memory. The stress hyperglycemia ratio (SHR) has emerged as a promising predictor of mortality compared to absolute glucose or HbA1c, with a proposed threshold of ≥1.14 identifying patients at 3.5-fold increased risk for mechanical ventilation. Precision management should consider the prudent suspension of SGLT2 inhibitors to mitigate euglycemic DKA risks and considering the early use of GLP-1 receptor agonists for their hypothesized pulmonary anti-inflammatory properties. Conclusions: Closing the mortality gap may require a shift from generic viral care to a precision model that treats metabolic susceptibility with high clinical priority alongside the treatment of the viral pathogen.Keywords
Funding Information
- Victor Babes University of Medicine and Pharmacy, Timisoara
This publication has 56 references indexed in Scilit:
- Developing a Protocol for Management of Euglycemic Diabetic KetoacidosisCurrent Diabetes Reports, 2025
- SARS-CoV-2, influenza, HRSV and other respiratory pathogens during the post-COVID-19 era: Epidemic circulation in Italy in the 2023/2024 seasonJournal of Infection and Public Health, 2025
- Seasonal influenza vaccination coverage and the social determinants of influenza vaccination among people over 50 with diabetes in Europe: Analyzing population-based SHARE data for the 2019–2020 and 2021–2022 influenza seasonsVaccine, 2024
- Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 yearsJournal of Infection, 2024
- Role of the receptor for advanced glycation end products in the severity of SARS-CoV-2 infection in diabetic patientsDiabetology International, 2024
- Severe respiratory syncytial virus diseaseJournal of Intensive Medicine, 2024
- A Critical Review on the Long-Term COVID-19 Impacts on Patients With DiabetesThe American Journal of Medicine, 2024
- Unraveling the gut-Lung axis: Exploring complex mechanisms in disease interplayHeliyon, 2024
- Severe Acute Respiratory Syndrome Associated InfectionsPhysician Assistant Clinics, 2023
- COVID-19 vaccination hesitancy in people affected by diabetes and strategies to increase vaccine compliance: A systematic narrative review and meta-analysisVaccine, 2023